Ind-Swift Laboratories share price
NSE: INDSWFTLABBSE: 532305Pharmaceuticals & BiotechnologySmall Cap
Ind-Swift Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1997 on NSE, Mar 2000 on BSE
Last close ₹368.80up ₹31.75 (9.42%)BSE ₹368.25
Share price at the NSE close on 27 Oct 2026. Previous close ₹337.05.
27 Oct: open ₹335.00, high ₹376.00, low ₹335.00
52-week range of traded prices to 27 Oct 2026
₹87.15Low, 31 Dec 2025₹424.75High, 30 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 27 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3,207 Cr1,404th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 55.95
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 46.77
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.32
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 4.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 5.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 8,50,81757.4% delivered
Results
Consolidated; ₹ crore.Ind-Swift Laboratories quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +113.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- –
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹191 Crup 12.76%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹25 Crup 63.34%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 12.9%
Revenue by quarter
Net profit by quarter, a loss in red
The quarters either side of a change of basis do not compare. From the quarter to Mar 2025, the company's revenue for the year to Mar 2025, ₹562 Cr, differs from its quarters added, ₹192 Cr. From the quarter to Mar 2026, the company's revenue for the year to Mar 2026, ₹641 Cr, differs from its quarters added, ₹626 Cr.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 9 | 138 | 153 | 153 | 151 | 170 | 191 |
| Net profit | 0 | 0 | 222 | 9 | 8 | 10 | 15 | 25 |
| Net margin | 3.5% | 0.1% | 160.8% | 5.7% | 5.2% | 6.3% | 8.9% | 12.9% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- Revenue
- ₹641 Cr
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹41 Crdown 83.47%
- Net margin
- 6.5%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 4 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2025, the company's revenue for that year, ₹562 Cr, differs from its quarters added, ₹192 Cr. From the year to Mar 2026, the company's revenue for that year, ₹641 Cr, differs from its quarters added, ₹626 Cr.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 718 | 765 | 757 | 780 | 891 | 1,039 | 1,207 | 1,281 | 562 | 641 |
| Net profit | −39 | 22 | 38 | −21 | −3 | −2 | 48 | 421 | 250 | 41 |
| Net margin | −5.4% | 2.9% | 5.1% | −2.7% | −0.4% | −0.2% | 3.9% | 32.9% | 44.6% | 6.5% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the years to Mar 2025 and Mar 2026: days before it are of the company before the change.Ind-Swift Laboratories PE ratio and valuation
Price to earnings
At or below today's level on 88% of 182 trading days over the last year.
LowestHighest
Its median32.42Industry median28.32
Price to book
At or below today's level on 99% of 1,790 trading days since Nov 2018.
LowestHighest
Its median0.61Industry median2.99
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +56.5% | −86.9% | +1,095.9% | 0.0% |
| 3 years | +33.5% | −16.0% | +59.0% | 0.0% |
| 5 years | +12.8% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 1 and 3 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2023, Mar 2025 and Mar 2026.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 1,357 | 0.12% | ₹0.05 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 640 | 0.12% | ₹0.02 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Ind-Swift Laboratories insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Others0 purchases, 1 saleNo purchase₹0.25 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹0.25 Cr
- Promoters and promoter group: no market trade · 1 off-market move
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Ind-Swift Laboratories competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 8 companies closest to Ind-Swift Laboratories in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 SMS PharmaceuticalsSMSPHARMA | 4,147 | 40.38 | 5.28 | +10.2% | +40.4% | 14.4% | 11.5% | 0.09% |
 Kwality PharmaceuticalsKPL | 3,735 | 46.08 | 11.26 | +37.9% | +86.7% | 27.2% | 25.0% | 0.00% |
 Aarti DrugsAARTIDRUGS | 3,671 | 19.20 | 2.37 | +10.5% | +1.2% | 13.1% | 12.4% | 0.50% |
 Unichem LaboratoriesUNICHEMLAB | 3,387 | 11.11 | 1.25 | +9.4% | – | 11.8% | 3.3% | 0.00% |
 Shukra PharmaceuticalsSHUKRAPHAR | 3,145 | 87.25 | 35.00 | +115.0% | +256.2% | 47.2% | 47.3% | 0.01% |
 Solara Active Pharma SciencesSOLARA | 3,072 | 83.16 | 2.14 | +27.3% | – | 2.7% | 6.4% | 0.00% |
 HikalHIKAL | 2,489 | – | 2.08 | −5.4% | −153.4% | −2.7% | 3.5% | 0.30% |
 Fredun PharmaceuticalsFREDUN | 2,452 | – | 8.82 | – | – | – | 18.8% | 0.02% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Ind-Swift Laboratories dividend history
| Ex-date | Type | Per share |
|---|---|---|
| 20 Sep 2011 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹1.00 |
| 16 Sep 2010 | Final | ₹1.00 |
| 17 Sep 2009 | Final | ₹1.00 |
| 18 Sep 2008 | Final | 10% of face valueDividend as a percentage of face value. Not sized in rupees: the face value of the share at the time is stated by only one record, so it is not checked. |
| 21 Sep 2007 | Final | 10% of face value (₹1.00 a share) |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Ind-Swift Laboratories announcements
Oct 2026
8 Oct
Sep 2026
Ind-Swift Laboratories share price by year
Each calendar year to 2025.Ind-Swift Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 88.15 | −18.8% | 120.15 | 70.13 |
| 2024 | 108.57 | +4.8% | 176.72 | 89.93 |
| 2023 | 103.55 | +49.1% | 123.40 | 54.25 |
| 2022 | 69.45 | +2.2% | 88.00 | 53.40 |
| 2021 | 67.95 | +9.2% | 122.20 | 57.65 |
| 2020 | 62.25 | +166.0% | 70.85 | 15.70 |
| 2019 | 23.40 | −51.9% | 48.60 | 22.25 |
| 2018 | 48.65 | −36.5% | 104.75 | 48.50 |
| 2017 | 76.60 | +111.6% | 76.60 | 32.80 |
| 2016 | 36.20 | −2.4% | 53.85 | 34.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 26 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 26 Oct 2026 | 320.00 | 344.20 | 316.00 | 337.05 | 336.32 | 4,14,766 | 47.2% |
| 23 Oct 2026 | 345.00 | 348.70 | 321.15 | 327.45 | 330.50 | 6,58,248 | 52.8% |
| 22 Oct 2026 | 337.00 | 350.55 | 336.00 | 345.35 | 343.25 | 2,69,569 | 44.4% |
| 21 Oct 2026 | 353.00 | 366.00 | 336.80 | 342.50 | 345.45 | 6,44,437 | 59.4% |
| 19 Oct 2026 | 358.85 | 364.00 | 350.00 | 351.90 | 357.07 | 2,30,552 | 49.8% |
| 16 Oct 2026 | 358.00 | 370.00 | 352.00 | 359.25 | 360.42 | 3,09,979 | 40.9% |
| 15 Oct 2026 | 366.90 | 377.20 | 355.00 | 357.95 | 363.59 | 2,62,152 | 45.0% |
| 14 Oct 2026 | 363.00 | 374.85 | 356.25 | 369.70 | 367.16 | 3,54,561 | 51.4% |
| 13 Oct 2026 | 363.50 | 367.25 | 345.00 | 361.35 | 354.68 | 3,65,436 | 44.6% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- INDSWFTLAB
- BSE code
- 532305
- ISIN
- INE915B01019
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.indswiftlabs.com
- CIN
- L24232CH1995PLC015553
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1995
- Registered office
- SCO:850, Shivalik Encalve, NAC, Manimajra, Chandigarh 160101, Chandigarh
- Share registrar
- Alankit Assignments Ltd
- Keeps the register of shareholders and handles transfers and dividend payments